**Document 12 – LSD Medicines**  (for information only)

For information only: list of drugs currently commissioned and drugs that may be available to commission during the life of the Framework.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **DRUG NAME** | **NICE APPROVED ENGLAND** | **NHS England Commissioned** | **SMC APPROVED FOR USE SCOTLAND** | **NHS Scotland Commissioned** | **Not yet approved/commissioned but chance may be in life of Framework** | **Comments** |
| Laronidase (Aldurazyme) |  | y | n | y (if IPTR/PACE approved) |  |  |
| Idursulfase (Elaprase) |  | y | n | y (if IPTR/PACE approved) |  |  |
| Galsulfase (Naglazyme) |  | y | not submitted | n |  |  |
| Agalsidase Beta (Fabrazyme) |  | y | n(pre SMC) | y |  |  |
| Imiglucerase (Cerezyme) |  | y | n (pre SMC) | y |  |  |
| Alglucosidase Alfa (Myozyme) |  | y | n | y (if IPTR/PACE approved) |  |  |
| Avalglucosidase alfa  (Nexviazyme) | y | y |  |  |  |  |
| Agalsidase Alfa (Replagal) |  | y | n (pre SMC) | y |  |  |
| Velaglucerase (VPRIV) |  | y | y | y |  |  |
| Migalastat (Galafold) | y | y | y | y |  |  |
| Miglustat (Zavesca) |  | y | y | y (for Type 1 Gauchers) | y (Nipmann-Pick type C) |  |
| Eliglustat (Cerdelga) | y | y | y | y |  |  |
| Elosulfase Alfa | y | y | n | n |  |  |
| Sebelipase Alfa | N | N |  |  | y |  |
| Pegunigalsidase alfa (PRX‑102) | N | N |  |  | y |  |
| Cipalglucosidase alfa | N | N |  |  | y |  |
| Mepsivi | N | N |  |  |  |  |
| Olipudase alfa | N | N |  |  | y |  |
| Vestronidase alfa | N | In development |  |  | y |  |
| intrathecal idursulfase | n | n |  |  | y | may replace the use of the IV version |
| **There are new SRT and new ERT drugs that are going through the licensing process and appraisal by NICE. These are highlighted in yellow. If approved Sebelipase alfa and olipudase alfa would be treatments for new cohorts of patients. Cipalglucosidase alfa and pegunigalsidase alfa would be new treatment options for Pompe and Fabry respectively if approved. it is not known at this time if these drugs will be approved for routine commissioning during the lifetime of the framework. Other new therapies may also be approved during the lifetime of the framework.** | | | | | | |